Modulatory role of adenosine and its receptors in epilepsy: Possible therapeutic approaches

Neuroscience Research

Volumn 56, Issue 1, 2006, Pages 14-20

  Pagonopoulou, O ^a   Efthimiadou, A ^a   Asimakopoulos, B ^a   Nikolettos, N K ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Adenosinergic system; Epilepsy modulation; Therapeutic approach

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AGGRESSION; ANEMIA; BEHAVIOR DISORDER; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CELL BASED GENE THERAPY; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; DRUG ERUPTION; EPILEPSY; EPILEPTOGENESIS; HEART PROTECTION; HEART RATE; HUMAN; NEUROBIOLOGY; NEUROPHARMACOLOGY; NOCICEPTION; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; RESPIRATION CONTROL; REVIEW; SEIZURE; THERMOREGULATION; TISSUE ENGINEERING; VISUAL FIELD DEFECT;

ADENOSINE; ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; PROTEIN ISOFORMS; RECEPTORS, PURINERGIC P1;

EID: 33748786244     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2006.05.010     Document Type: Review

References (84)

1. Aden U., O'Connor W.T., and Berman R.F. Changes in purine levels and adenosine receptors in kindled seizures in the rat. Neuroreport 15 10 (2004) 1585-1589
2. Angelatou F., Pagonopoulou O., Maraziotis M.T., et al. Upregulation of A1 adenosine receptors in human temporal lobe epilepsy: a quantitative autoradiographic study. Neurosci. Lett. 163 (1993) 11-14
3. Angelatou F., Pagonopoulou O., and Kostopoulos G. Changes in seizure latency correlate with alterations in A1 adenosine receptor binding during daily repeated pentylentetrazol-induced convulsions in different mouse brain areas. Neurosci. Lett. 132 (1991) 203-206
4. Barraco R.A., Helfman C.C., Goodwin B.P., and Anderson G.F. Evidence for presynaptic adenosine A2A receptors associated with norepinephrine release and their desensitisation in the rat nucleus tractus solitarius. J. Neurochem. 65 (1995) 1604-1611
5. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 3 (2004) 618-621
6. Berkovic S.F., and Scheffer I.E. Genetics of the epilepsies. Epilepsia 42 (2001) 16-23
7. Berkovic S.F. Treatment with antiepileptic drugs. Aust. Fam. Phys. 34 12 (2005) 1017-1020
8. Berman R.F., Fredholm B.B., Aden U., and O'Connor W.T. Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. Brain Res. 872 (2000) 44-53
9. Biber K., Klotz K.N., Berger M., Gebicke-Harter P.J., and van Calker D. Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. 17 (1997) 4956-4964
10. Blood A.B., Hunter C.J., and Power G.G. The role of adenosine in regulation of cerebral blood flow during hypoxia in the near-term fetal sheep. J. Physiol. 543 Pt 3 (2002) 1015-1023
11. Boison D. Adenosine and Epilepsy: from therapeutic rationale to new therapeutic strategies. The Neuroscientist 11 1 (2005) 25-36
12. Boison D., Scheurer L., Tseng J.L., Aebischer P., and Mohler H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol. 160 (1999) 164-174
13. Brodie M.S., Lee K.S., Fredholm B.B., et al. Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action. Brain Res. 415 (1987) 323-333
14. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalo-graphic classification of epileptic seizures. Epilepsia 22 (1981) 489-501
15. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30 (1989) 389-399
16. Concas A., Santoro G., Mascia M.P., et al. Anticonvulsant doses of 2-chloro-N6 cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J. Pharmacol. Exp. Ther. 267 (1993) 844-851
17. Copp A.J., and Harding B.N. Neuronal migration disorders in humans and in mouse models-an overview. Epilepsy Res. 36 2/3 (1999) 133-141
18. Correia-de-Sa P., and Ribeiro J.A. Tonic adenosine A2A receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. Eur. J. Pharmacol. 271 (1994) 349-355
19. Coulter D.A. Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties. Int. Rev. Neurobiol. 45 (2001) 237-252
20. Cuhna R.A. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinerg. Signall. 1 (2005) 111-134
21. Cunha R.A., and Ribeiro J.A. Purinergic modulation of [3H] GABA release from rat hippocampal nerve terminals. Neuropharmacology 39 (2000) 1156-1167
22. 3H] acetylcholine release from different areas of the rat hippocampus. J. Neurochem. 63 (1994) 207-214
23. De Sarro G., De Sarro A., and Di Paola E.D. Effects of adenosine receptor agonists and antagonists on audiogenic seizure sensible DBA/2 mice. Eur. J. Pharmacol. 371 (1999) 137-145
24. Dichter M.A., and Ayala G.F. Cellular mechanisms of epilepsy: a status report. Science 237 (1987) 157-164
25. Doriat J.-F., Koziel V., Humbert A.-C., and Daval J.-L. Medium- and long-term alterations of brain A1 and A2A adenosine receptor characteristics following repeated seizures in developing rats. Epilepsy Res. 35 (1999) 219-228
26. Dragunow M. Adenosine: the brain's natural anticonvulsivant?. Trends Pharmacol. Sci. 7 (1986) 128-130
27. Dunwiddie T.V., and Masino S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24 (2001) 31-55
28. Dunwiddie T.V., Diao L.H., Kim H.O., Jiang J.L., and Jacobson K.A. Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17 (1997) 607-614
29. During M.J., and Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32 (1992) 618-624
30. Ekonomou A., Sperk G., Kostopoulos G., and Angelatou F. Reduction of A1 adenosine receptors in rat hippocampus after kainic acid-induced limbic seizures. Neurosci. Lett. 284 (2000) 49-52
31. Engel Jr. J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42 (2001) 796-803
32. Fastbom J., Pazos A., and Palacios J.M. The distribution of adenosine A1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22 (1987) 813-826
33. Feoktistov I., and Biaggioni I. Adenosine A2B receptors. Pharm. Rev. 49 (1997) 381-402
34. Ferre S., Ciruela F., Woods A.S., et al. Glutamate mGlu5-adenosine A2A-dopamine D2 receptor interactions in the striatum. Implications for drug therapy in neuro-psychiatric disorders and drug abuse. Curr. Med. Chem. 3 (2003) 1-26
35. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
36. Fredholm B.B., Cunha R., and Svenningsson P. Pharmacology of adenosine A2A receptors and therapeutic applications. Curr. Top. Med. Chem. 3 (2003) 413-426
37. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy. Neurology 62 (2004) 1252-1260
38. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of refractory epilepsy. Neurology 62 (2004) 1261-1273
39. Gebicke-Haerter P.J., Christoffel F., Timmer J., Northoff H., Berger M., and Van Calker D. Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem. Int. 29 (1996) 37-42
40. Glass M., Faull R.L., Bullock J.Y., et al. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 710 (1996) 56-68
41. Gouder N., Fritschy J.-M., and Boison D. Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia 44 7 (2003) 877-885
42. Gourine A.V. On the peripheral and central chemorception and control of breathing: an emerging role of ATP. J. Physiol. 568 Pt 3 (2005) 715-724
43. Gourine A.V., Melenchuk E.V., Poputnikov D.M., Gourine V.N., and Spyer K.M. Involvement of purinergic signalling in central mechanisms of body temperature regulation in rats. Br. J. Pharmacol. 135 8 (2002) 2047-2055
44. Guttinger M., Padrun V., Pralong W.F., and Boison D. Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp. Neurol. 193 (2005) 53-64
45. Hirose S., Okada M., Kaneko S., and Mitsudome A. Are some idiopathic epilepsies disorders of ion channels? A working hypothesis. Epilepsy Res. 41 (2000) 191-204
46. Huber A., Guttinger M., Mohler H., and Boison D. Seizure suppression by adenosine A2A receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci. Lett. 329 (2002) 289-292
47. Huber A., Padrun V., Deglon N., Aebischer P., Mohler H., and Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7611-7616
48. Isenmann S., Brandner S., and Aguzzi A. Neuroectodermal grafting: a new tool for the study of neurodegenerative diseases. Histol. Histopathol. 11 (1996) 1063-1073
49. Isenmann S., Brandner S., Sure U., and Aguzzi A. Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathol. Appl. Neurobiol. 22 (1996) 108-117
50. Laudadio M.A., and Psarropoulou C. The A3 adenosine receptor agonist 2-Cl-IB-MECA facilitates epileptiform discharges in the CA3 are of immature rat hippocampal slices. Epilepsy Res. 59 (2004) 83-94
51. Lopes L., Cunha R.A., Kull B., Fredholm B.B., and Ribeiro J.A. Adenosine A2A receptor facilitation of hippocampal synaptic transmission is dependent on the tonic A1 receptor inhibition. Neuroscience 112 (2002) 319-329
52. Lopes L.V., Halldner L., and Rebola N. Binding of the prototypical adenosine A2A receptor agonist CGS 21680 to the cerebral cortex of adenosine A1 and A2A receptor knockout mice. Br. J. Pharmacol. 141 (2004) 1006-1014
53. Loscher W., and Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301 (2002) 7-14
54. Macdonald R.L., Skerritt J.H., and Werz M.A. Adenosine agonists reduce voltage dependent calcium conductance of mouse sensory neurones in cell culture. J. Physiol. 370 (1986) 75-90
55. Macek T.A., Schaffhauser H., and Conn P.J. Protein kinase C and A3 adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. J. Neurosci. 18 (1998) 6138-6146
56. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature 399 6738 Suppl. (1999) A15-A22
57. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 14 6 (1994) 3413-3425
58. Meldrum B.S., Akbar M.T., and Chapman A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. 36 (1999) 189-204
59. Minamino T., and Kitakaze M. Cellular mechanisms for the treatment of chronic heart failure: the nitric-oxide and adenosine dependent pathways. Expert Opin. Emerg. Drugs 7 1 (2002) 99-110
60. Monopoli A., Conti A., Dionissotti S., et al. Pharmacology of the highly selective A1 receptor agonist 2-chloro-N6 cyclopentyladenosine. Arzneimittelforschung 44 (1996) 1305-1312
61. Morimoto K., Fahnestock M., and Racine R. Kindling and status epilepticus models in epilepsy: rewiring the brain. Progr. Neurobiol. 73 (2004) 1-60
62. Moulard B., Picard F., le Hellard S., et al. Ion channel variation causes epilepsies. Brain Res. Brain Res. Rev. 36 (2001) 275-284
63. Ochiishi T., Takita M., Ikemoto M., Nakata H., and Suzuki S.S. Immunohistochemical analysis on the role of adenosine A1 receptors in epilepsy. Neuroreport 10 (1999) 3535-3541
64. 3H]- acetylcholine release from the rat motor nerve terminals. Eur. J. Neurosci. 15 (2002) 1728-1736
65. Olsson R.A., and Pearson J.D. Cardiovascular purinoceptors. Physiol. Rev. 70 (1990) 761-989
66. Othman T., Yan H., and Rivkees S.A. Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia 44 (2003) 166-172
67. Pagonopoulou O., Angelatou F., and Kostopoulos G. Effect of pentylentetrazol-induced seizures on A1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience 56 (1993) 711-716
68. Pedata F., Corsi C., Melani A., Bordoni F., and Latini S. Adenosine extracellular brain concentrations and role of A2A receptors in ischemia. Ann. N.Y. Acad. Sci. 939 (2001) 74-84
69. Porkka-Heiskanen T., Kalinchuk A., Alanko L., Urilla A., and Stenberg D. Adenosine, energy metabolism and sleep. Sci. World J. 20 3 (2003) 790-798
70. Rebola N., Coelho J.E., Costenla A.R., et al. Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur. J. Neurosci. 18 (2003) 820-828
71. Rebola N., Porciuncula L.O., Oliveira C.R., et al. Long-term effect of convulsive behaviour on the density of adenosine A1 and A2A receptors in the rat cerebral cortex2005. Epilepsia 46 Suppl. 5 (2005) 159-165
72. Rebola N., Sebastiao A.M., and de Mendonca A. Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J. Neurophysiol. 90 (2003) 1295-1303
73. Sadigh-Lindell B., Sylven C., Berglund M., and Eriksson B.E. Role of adenosine and opioid-receptor mechanisms for pain in patients with silent myocardial ischemia or angina pectoris: a double-blind, placebo-controlled study. J. Cardiovasc. Pharmacol. 42 6 (2003) 757-763
74. Sato K., Iwai M., Zhang W.R., et al. Highly polysialylated neural cell adhesion molecule (PSANCAM) positive cells are increased and change localization in rat hippocampus by exposure to repeated kindled seizures. Acta Neurochir. Suppl. 86 (2003) 575-579
75. Sebastiao A.M., and Ribeiro J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 21 (2000) 341-346
76. Shryock J.C., and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am. J. Cardiol. 79 (1997) 2-10
77. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Progr. Neurobiol. 59 (1999) 355-396
78. Tchekalarova J., Sotiriou E., Georgiev V., Kostopoulos G., and Angelatou F. Upregulation of adenosine A1 receptor binding in PTZ kindling in mice: effects of angiotensin IV. Brain Res. 1032 (2005) 94-103
79. Tetzlaff W., Schubert P., and Kreutzberg G.W. Synaptic and extrasynaptic localization of adenosine binding sites in the rat hippocampus. Neuroscience 21 (1987) 869-875
80. Trussel L.O., and Jackson M.B. Adenosine activated potassium conductance in cultured striatal neurons. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4857-4861
81. Vanore G., Giraldez L., Rodriguez de Lores Arnaiz G., and Girardi E. Seizure activity produces differential changes in adenosine A1 receptors within rat hippocampus. Neurochem. Res. 26 3 (2001) 225-230
82. von Lubitz D.K. Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept?. Eur. J. Pharmacol. 371 (1999) 85-102
83. Young D., and Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 58 (1994) 245-261
84. Zuchora B., Wielosz M., and Urbanska E.M. Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. Eur. J. Neuropsychopharm. 15 (2005) 85-93